Patent
Anti-invasive compounds
TLDR
In this paper, a method for predicting the anti-invasive activity of chalcone-like compounds was proposed. But this method is not suitable for the use in the prevention and/or treatment of diseases associated with undesired cell invasion.Abstract:
The present invention relates to the field of anti-invasive compounds and methods for predicting the anti-invasive activity of said compounds, as well as their use in the prevention and/or treatment of diseases associated with undesired cell invasion; in particular, this invention relates to the field of anti-invasive chalcone-like compounds.read more
Citations
More filters
Patent
1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
TL;DR: In this paper, compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers:
Patent
Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
John Hood,Kc Sunil Kumar +1 more
TL;DR: In this article, the use of indazole-3-carboxamide compounds or analogs thereof in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis) was disclosed.
Patent
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
TL;DR: In this article, the use of indazole compounds or analogs thereof in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease and osteoarthritis) was disclosed.
Patent
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
TL;DR: Azaindazole compounds for treating various diseases and pathologies are disclosed in this article, where the use of an azaindaxole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis) is discussed.
Patent
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
TL;DR: Azaindazole compounds for treating various diseases and pathologies are disclosed in this paper, where the use of an azaindaxole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis) is discussed.
References
More filters
Journal ArticleDOI
Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
TL;DR: A tetrazolium salt has been used to develop a quantitative colorimetric assay for mammalian cell survival and proliferation and is used to measure proliferative lymphokines, mitogen stimulations and complement-mediated lysis.
Journal ArticleDOI
Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines
George J. Todaro,Howard Green +1 more
TL;DR: Disaggregated mouse embryo cells, grown in monolayers, underwent a progressive decline in growth rate upon successive transfer, the rapidity of the decline depending on the inoculation density, but nearly all cultures developed into established lines within 3 months of culture.
Journal ArticleDOI
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
TL;DR: In vivo selection of phage display libraries was used to isolate peptides that home specifically to tumor blood vessels that enhanced the efficacy of the anticancer drug doxorubicin and reduced its toxicity.
Journal ArticleDOI
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.
Selma Pennacchietti,Paolo Michieli,Maria Galluzzo,Massimiliano Mazzone,Silvia Giordano,Paolo M. Comoglio +5 more
TL;DR: It is shown that hypoxia promotes tumor invasion by sensitizing cells to HGF stimulation, providing a molecular basis to explain Met overexpression in cancer.
Journal ArticleDOI
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
TL;DR: Adding bevacizumab to chemotherapy failed to increase survival in patients with previously treated and refractory metastatic breast cancer, and addition of vatalanib, a kinase inhibitor developed as a VEGF receptor-selective agent, to chemotherapy did not show a similar benefit in metastatic colorectal cancer patients.